Wednesday 1 May | |
J Sainsbury | Full Year Results |
Connect Group | Half Year Results |
Indivior | Q1 Results |
AIB Group | Q1 Results |
London Stock Exchange Group | Q1 Results |
Metro Bank | Q1 Results |
IWG | Q1 Results |
Inmarsat | Q1 Results |
Next | Q1 Results |
Persimmon | Trading Statement |
GlaxoSmithKline | Q1 Results (at 1200 BST) |
Rank Group | Trading Statement |
RPS Group | Trading Statement |
Avon Rubber | Half Year Results |
Nichols | Trading Statement |
Thursday 2 May | |
Royal Dutch Shell | Q1 Results |
Coca-Cola HBC | Q1 Results |
Smith & Nephew | Q1 Results |
Lloyds Banking Group | Q1 Results |
Lancashire Holdings | Q1 Results |
Paddy Power Betfair | Q1 Results |
Reckitt Benckiser | Q1 Results |
Schroders | Q1 Results |
Indivior | Q1 Results |
N Brown Group | Full Year Results |
Equiniti | Trading Statement |
James Fisher & Sons | Trading Statement |
Reach | Trading Statement |
International Personal Finance | Trading Statement |
Friday 3 May | |
HSBC Holdings | Q1 Results (at 0500 BST) |
Smurfit Kappa | Q1 Results |
Numis | Half Year Results |
intu Properties | Trading Statement |
ConvaTec | Q1 Results |
InterContinental Hotels Group | Q1 Results |
Ultra Electronics | Trading Statement |
Monday 6 May | |
no events scheduled | |
Tuesday 7 May | |
Domino's Pizza Group | Q1 Results |
Hiscox | Q1 Results |
Treatt | Half Year Results |
Vivo Energy | Q1 Results |
Faron Pharmaceuticals | Full Year Results |
IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.
Read more